Browsing NTNU Open by Author "Sandlie, Inger"

Now showing items 1-3 of 3

    • Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation 

      Lau, Corinna; Gunnarsen, Kristin Støen; Høydahl, Lene Støkken; Andersen, Jan Terje; Berntzen, Gøril; Pharo, Anne Margrethe; Lindstad, Julie Katrine; Ludviksen, Judith K; Brekke, Ole Lars; Barratt-Due, Andreas; Nielsen, Erik Waage; Stokes, Christopher R.; Espevik, Terje; Sandlie, Inger; Mollnes, Tom Eirik (Journal article; Peer reviewed, 2013)
      CD14 is a key recognition molecule of innate immune responses, interacting with several TLRs. TLR signaling cross-talks extensively with the complement system, and combined CD14 and complement inhibition has been proved ...

    • Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn 

      Hallstensen, Randi; Bergseth, Grete; Foss, Stian; Jæger, Steinar; Gedde-Dahl, Thobias; Holt, jan; Christiansen, Dorte; Lau, Corinna; Brekke, Ole Lars; Armstrong, Elina; Stefanovic, Vedran; Andersen, Jan Terje; Sandlie, Inger; Mollnes, Tom Eirik (Journal article; Peer reviewed, 2015)
      Eculizumab is a humanized IgG2/4 chimeric anti-complement C5 antibody used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome. The aim of this study was to evaluate whether ...

    • A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery 

      Benjakul, Sopisa; Anthi, Aina Karen; Kolderup, Heidi Anette; Vaysburd, Marina; Lode, Heidrun Elisabeth; Mallery, D; Fossum, Even; Vikse, Elisabeth Lea; Albecka, Anna; Ianevski, Aleksandr; Kaynov, Denis; Karlsen, Karine Flem; Sakya, Siri Aastedatter; Nyquist-Andersen, Mari; gjølberg, torleif; Moe, Morten Carsten; Bjørås, Magnar; Sandlie, Inger; James, Leo C.; Andersen, Jan Terje (Peer reviewed; Journal article, 2023)
      Immunocompromised patients often fail to raise protective vaccine-induced immunity against the global emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Although monoclonal antibodies have ...